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1622Pulmonary vascular resistance
(PVR) has important implications
for the management and prognosis
in patients with pulmonary hy-
pertension (PH) (1) and chronic
heart failure (2). Moreover, mean
pulmonary artery (PA) pressure,
and/or PVR response during acute
vasodilator testing correlates with
prognosis (3–5) and helps guiding
physicians with the selection of
appropriate therapy (1,6,7).
Currently, both acute vasodi-
lator testing and PVR monitoring
require invasive right heart cath-
eterization (RHC). An accuratenoninvasive alternative would be helpful to eliminate the
discomfort, radiation exposure, and small but real risk of
morbidity and mortality associated with RHC (8). Doppler
echocardiography has become routine in the follow-up of
patients with PH due to its ability to estimate systolic PA
pressure, but has limited accuracy (9) and applicability (i.e.,
poor acoustic window or absence of tricuspid regurgitation)
and it is not widely accepted for PVR estimation (10).
Cardiac magnetic resonance (CMR) has been proposed as an
alternative in assessing pulmonary hemodynamics non-
invasively (11–15). It has been previously demonstrated that
average PA ﬂow velocity correlates strongly with PVR, and
that CMR allows for noninvasive estimation of PVR values
(16). However, whether CMR can accurately monitor serial
changes in PVR is unknown. Therefore, our aim was to
determine the ability of CMR to track acute and chronic
ﬂuctuations in PVR from serial changes in average PA
velocity and CMR-estimated PVR.
Methods
Study design and experimental models. Experimental
procedures were performed in castrated male Large-White
pigs. The study was approved by the Institutional Animal
Research Committee and carried out in compliance with the
Guide for the Care and Use of Laboratory Animals. Before
any procedure, anesthesia was induced by intramuscular
injection of ketamine (20 mg/kg), xylazine (2 mg/kg), and
midazolam (0.5 mg/kg), with buprenorphine (0.3 mg/kg)
for analgesia, and the animals were intubated. All CMR and
hemodynamic measures were obtained during spontaneous
ventilation, anesthesia maintained with intravenous mida-
zolam (0.2 mg/kg/h), and continuous electrocardiographic
and oxymetric monitoring.
The ability of CMR to detect changes in PVR was
evaluated under 3 different conditions:
1. Acute PH (n ¼ 10), generated inside the mag-
net by pulmonary embolization with polydextrane-
microspheres with a diameter of 300 mm (Sephadex
G50, Pharmacia Biotech GmbH, Freiburg, Germany)(17) through the femoral vein. Each animal received
a different dose from a suspension with 2.5 mg of
microspheres per milliliter of saline (between 100 and
400 mg, median of 200 mg) in order to achieve a wide
range of acute PH severity. CMR imaging with
simultaneous hemodynamic monitoring was per-
formed immediately pre- and post-embolization.
2. Chronic PH (n ¼ 22), using 2 different models.
Pre-capillary PH (n¼ 9) was generated with repeated
microsphere embolization in a variant of a model previ-
ously described (18), using similar methodology as em-
ployed in the acute model but during mechanical
ventilation. The ﬁrst pulmonary embolization was per-
formed in 3-month-old pigs (weight z40 kg) and
repeated weekly until chronic stable PH was generated
(meanPA pressure25mmHg at rest). Amedian of 4
embolizations (range 3 to 6) with a median dose
of microspheres of 500 mg was required to induce
sustained PH.
Post-capillary PH (n ¼ 13) was generated by
surgical nonrestrictive banding of the main pulmonary
vein (venous conﬂuent arising from the junction of
both inferior pulmonary veins) through a small
thoracotomy in 4-week-old piglets (weightz10 kg),
a variant of a model previously described (19). This
venous conﬂuent drains both inferior pulmonary
lobes, which account for z80% of total lung mass
(Figs. 1A and 1B). Restriction of ﬂow and secondary
PH arise progressively as the animal grows. Animals
were maintained with inhaled sevoﬂuorane (1.5% to
2.0%) during the procedure under mechanical venti-
lation. The external jugular vein and internal carotid
artery were dissected and cannulated for continuous
recording of systemic and PA pressures. There was no
perioperative mortality but 2 animals died suddenly
during the follow-up period (2 and 3 months after the
operation).CMR studies with simultaneous hemody-
namic monitoring were performed at baseline, once
chronic PH was generated, and every 4 weeks there-
after for 2 and 4 months, in the pre- and post-capillary
models, respectively.
3. Acute vasodilator testing (n¼ 10 animals with chronic
PH; 5 with pre- and 5 with post-capillary PH) was
performed inside the magnet by increasing the inhaled
oxygen concentration to 100%with all other conditions
in steady state. CMR imaging with simultaneous
hemodynamic monitoring was performed immediately
before and 5 min after oxygen administration.
Invasive hemodynamic assessment. Hemodynamic measure-
ments, obtained using a Swan-Ganz catheter via femoral or
internal jugular vein, included mean PA pressure, pulmonary
capillary wedge pressure (PCWP) at end-expiration, and cardiac
output assessed by thermodilution. PVR was calculated as the
difference between mean PA pressure and the estimated left
atrial pressure divided by the cardiac output in Wood units
Figure 1 Selective Nonrestrictive Banding of the Venous Conﬂuent Draining Both Inferior Pulmonary Lobes
(A) Diagram shows the anatomy of the pulmonary venous circulation and its drainage pattern into the left atrium in pigs. The inferior venous conﬂuent has been encircled.
(B) Surgical photograph showing the banding of the venous conﬂuent at the exact resting diameter.
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1623(WU). In animals with pre-capillary PH, PCWP was used as an
estimate of left atrial pressure (mean difference between PCWP
and left ventricular end-diastolic pressure of 0.8 mm Hg in
a pilot study, N ¼ 12), whereas in animals with post-capillary
PH, left ventricular end-diastolic pressure quantiﬁed with
a pigtail catheter was used, due to the variation of PCWP
measurements amongst pulmonary lobes. Cardiac output and
PVR were also indexed by body surface area estimated by the
Brody’s formula (20). Immediately after RHC, the Swan-Ganz
catheter was replaced for a CMR-compatible version (Edwards,
Irvine, California) and the animal was transferred to the CMR
suite, adjacent to the catheterization laboratory.
CMR studies. CMR ACQUISITION. All CMR studies were
performed with a 3.0-T magnet (Achieva-Tx, Philips Me-
dical Systems, Best, the Netherlands), equipped with a 32-
channel cardiac phased-array surface coil and retrospective
electrocardiographic gating. Images were obtained with
simultaneous monitoring of PA and systemic pressures using
a CMR-compatible monitor (Invivo, Orlando, Florida).
Steady-state free precession cine sequences were acquired in
10 to 15 contiguous short axis slices covering both ventricles
from base to apex, and reconstructed into 25 cardiac phases
each for the evaluation of ventricular volumes and function.
Two-dimensional ﬂow imaging (phase-contrast) was per-
formed perpendicular to themain PAwith a velocity-encoded
gradient echo sequence using the minimum upper velocity
limit without signal aliasing. For this purpose, 2 double-
oblique orthogonal views oriented along the main axis of the
PA trunk were acquired with a standard steady-state free
precession cine sequence and used as the reference to prescribe
a plane perpendicular to the main PA for the acquisition of
phase-contrast images (Fig. 2). Similarly, 2D ﬂow imaging in
a cross-sectional view of the ascending aorta was obtainedto determine left cardiac output. The following imaging
parameters were applied for 2D ﬂow imaging: repetition time/
echo time 5.4/3.4 ms; number of averages 2; slice thickness 8
mm; voxel size 2.5  2.5 mm; reconstructed heart phases 40.
In chronic PH animals, 2D ﬂow imaging was performed at
each visit. The agreement between cardiac output obtained
by aortic 2D ﬂow imaging and thermodilution was excellent
(0.1  0.4 l/min; R ¼ 0.92, p < 0.01). Thus, in the acute
models, where thermodilution could not be performed inside
themagnet, cardiac output as assessed by phase-contrast of the
aorta was used to compute PVR immediately before and after
the intervention. In animals with chronic PH, 3D ﬂow
imaging on the main PA was additionally acquired.
CMR ANALYSIS. Short-axis steady-state cine and 2D phase-
contrast acquisitions were analyzed using specialized soft-
ware (Extended MR Workspace, Philips Medical Systems).
Observers were blinded to the study arm and hemodyna-
mic measurements. On cine images, biventricular endocardial
contours were manually traced in end-diastole and end-systole
and Simpson’s method was used to calculate volumes and
ejection fraction. Right ventricular (RV) trabeculations were
included within the blood pool. Similarly, the inner contours
of the main PA and aorta cross sections were outlined in each
cardiac phase to quantify the average velocity during the
complete cardiac cycle, minimum and maximum areas, and
cardiac output. No phase-offset correction was performed, as
the bias was negligible (data not shown). In a pilot study, we
conﬁrmed that the presence of the Swan-Ganz catheter inside
the PA did not cause signiﬁcant error in the estimation of
average PA ﬂow velocity (intraclass correlation coefﬁcient of
0.95 and mean bias of 0.2 cm/s). PA elasticity was calcula-
ted as: (maximal area – minimal area)/minimal area  100.
Figure 2 Phase Contrast Imaging of the Main PA
(A, B) Double-oblique orthogonal views oriented along the main axis (yellow line) of the pulmonary arterial (PA) trunk acquired with a steady-state free precession cine
sequence. (C, D) Phase-contrast imaging on the main PA ([C] anatomic view, [D] ﬂow-encoded view). White arrow in C represents Swan-Ganz catheter inside the
pulmonary artery encircled in red.
García-Álvarez et al. JACC Vol. 62, No. 17, 2013
Monitoring Pulmonary Vascular Resistance and Vasodilation With CMR October 22, 2013:1621–31
1624CMR-estimated PVR was calculated using the formula
previously validated (16) as: PVR (WU) ¼ 19.38 – [4.62 
ln PA velocity (cm/s)] – [0.08  RV ejection fraction (%)].
3D-phase-contrast acquisitions were analyzed using GTFlow
package (Gyrotools Inc., Zurich, Switzerland). PA was
segmented semiautomatically using morphological operators
and blood ﬂow pathlines were generated for the qualitative
assessment of ﬂow patterns and detection of vortices (21).
Histopathology. At the completion of the study, animals
with chronic PH were euthanized with a lethal injection of
pentobarbital sodium and the heart, PA, and lung parenchyma
were excised. Macroscopic high-resolution photographs were
taken using a digital camera. Standard hematoxylin and eosin
staining, and picrosirius red and Masson’s trichrome staining
were performed to evaluate microscopic changes and the
presence of collagen in order to demonstrate typical lesions
in the chronic PH models. A stereomicroscope Nikon SMZ
1500 (Nikon Instruments Inc., Melville, New York) was used.
Statistical analysis. Continuous variables are expressed as
median (interquartile range or range). For the evaluation of
serial changes in PVR (second condition), average PA
velocity was natural logarithm-transformed because itsassociation with PVR in chronic PH is curvilinear, as pre-
viously described (16). Correlation between acute changes in
PA velocity and PVR induced by pulmonary embolization or
vasodilator testing was assessed using Pearson correlation.
Mixed model analysis with correction for repeated mea-
surements was used to correlate changes in PVR and changes
in PA velocity in chronic PH, and to develop an equation to
predict the change in PVR per percent change in PA velocity.
Changes in PVR and PA velocity in chronic PH were
calculated as the difference between measurements in 2
consecutive follow-up visits. Changes in PA velocity and
PVR were further dichotomized to assess sensitivity, speci-
ﬁcity, and positive and negative predictive values of a reduc-
tion of PA velocity to detect an increase in PVR. Analyses
were performed using STATA version 12 (StataCorp LP,
College Station, Texas) and SPSS version 20 (IBM Corp.,
Armonk, New York).Results
Ability of CMR to track changes in PVR. ACUTE PH. Acute
pulmonary embolization caused an increase in PVR (median
Table 1 Changes in Hemodynamic and Phase Contrast Parameters During Acute Embolization
Baseline Post-Embolization Change p Value
Heart rate, beats/min 76.0 (14.0) 80.5 (24.0) 2.0 (14 to 27) 0.39
Oxygen saturation, % 97.5 (5.0) 94.5 (16.0) 3.5 (24 to 6) 0.12
Mean BP, mm Hg 92.0 (26.0) 85.5 (33.25) 6.5 (43 to 7) 0.07
Mean PA pressure, mm Hg 18.0 (10.0) 37.5 (12.0) 17.5 (5.0 to 32.0) <0.01
Cardiac output, l/min 3.7 (1.7) 2.7 (1.3) 0.7 (–2.7 to 0.5) 0.02
PCWP, mm Hg 11.5 (3.0) 11.5 (4.3) 0 (–1 to –1) 1.00
PVR, Wood units 1.8 (2.2) 10.0 (4.9) 6.8 (1.4 to 11.7) <0.01
PA ﬂow velocity, cm/s 13.5 (6.5) 8.5 (3.9) 4.9 (0.1 to 11.0) <0.01
PA minimal area, cm2 3.6 (1.3) 5.6 (2.8) 1.6 (0.2 to 3.8) <0.01
PA elasticity, % 28.6 (24.5) 15.1 (11.4) 9.6 (38 to 7) 0.04
Values at baseline and post-embolization are median (interquartile range) and change is expressed as median (minimum to maximum).
BP ¼ blood pressure; IQR ¼ interquartile range; PA ¼ pulmonary artery; PCWP ¼ pulmonary capillary wedge pressure; PVR ¼ pulmonary vascular
resistance.
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16256.8 WU; range 1.4 to 11.7 WU) and mean PA pressure
(median 17.5 mm Hg; range 5 to 32 mm Hg) with a
reduction in cardiac output (median 0.7 l/min; range 0 to 2.7
l/min). These hemodynamic changes were accompanied by
a signiﬁcant decrease in PA velocity, an increase in PA area,
and a reduction in PA elasticity (Table 1).
The magnitude of the fall in PA velocity strongly corre-
lated with the increment in PVR (r ¼ –0.92, p < 0.001)
(Fig. 3A). The change in PVR moderately correlated with
the change in PA elasticity (r ¼ –0.63, p¼ 0.05) and did not
correlate with the change in PA area (r ¼ 0.30, p ¼ 0.39).
CHRONIC PH. Baseline and follow-up characteristics of the
chronic PH animals are shown in Tables 2 and 3.
An increase in cardiac output along the follow-up related
with animal growth was observed in both models. Changes in
PVR between follow-up visits were greater in the post-
capillary model compared to the pre-capillary model (median
0.5 WU [range –5.4 to 19.0 WU] vs. median 0.1 WU [range
–2.5 to 2.6 WU], respectively; p ¼ 0.08).
Serial changes in between-visits PA velocity by CMR
strongly correlated with changes in PVR (r¼ –0.89, p< 0.01)2
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Figure 3 Correlation Between Changes in PVR and Changes in Avera
(A) Acute pulmonary embolization, (B) chronic pulmonary hypertension, (C) acute vasod
WU ¼ Wood units.(Fig. 3B). According to the equation obtained: change in
PVR (WU) ¼ –0.2 – 11.2  change in ln[PA velocity
(cm/s)], it can be estimated that average PVR increased
approximately 1 WU for each 10% decrease in PA velocity.
Subgroup analysis showed better correlation in the post-
capillary than the pre-capillary model (r ¼ –0.92, p < 0.01
vs. r ¼ –0.76, p < 0.01; p value for the interaction <0.01).
Figure 4 shows some examples of the evolution of PVR and
PA velocity during follow-up. Sensitivity, speciﬁcity, positive
predictive value, and negative predictive values for a reduction
in PA velocity to detect an increase in PVR were 86%,
70%, 79%, and 79%, respectively. Serial changes in between-
visits PVR moderately correlated with changes in PA area
(r ¼ 0.61, p < 0.01) and changes in PA elasticity (r ¼ –0.50,
p < 0.01). Serial changes in between-visits PA velocity by
CMR also correlated well with changes in indexed PVR
(r ¼ –0.82, p < 0.01). Animal weight and heart rate did not
behave as confounders on the association between changes in
PA velocity and PVR.
The concordance between absolute values of invasive PVR
and CMR-estimated PVR during follow-up using the
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ilator testing. PA ¼ pulmonary artery; PVR ¼ pulmonary vascular resistance;
Table 2 Baseline and Follow-Up Characteristics of Chronic Pre-Capillary PH Group
Chronic PH
Baseline At Generation After 1 Month After 2 Months
Weight, kg 40.0 (15.0) 55.0 (16.0) 68.5 (4.0) 81.0 (4.0)
Body surface area, m2 1.0 (0.23) 1.2 (0.2) 1.4 (0.1) 1.6 (0.05)
Heart rate, beats/min 75.0 (8.0) 75.0 (16.0) 70.0 (10.0) 74.0 (13.0)
Oxygen saturation, % 94.0 (6.0) 90.0 (2.0) 94.0 (3.0) 92.0 (3.0)
Mean BP, mm Hg 97.0 (9.0) 95.0 (16.0) 97.0 (9.0) 103 (9.0)
Mean PA pressure, mm Hg 21.0 (9.0) 28.0 (3.0) 27.0 (5.0) 27.0 (3.0)
Cardiac output, l/min 4.3 (1.0) 6.2 (1.1) 6.0 (1.6) 7.2 (1.4)
Cardiac index, l/min/m2 4.1 (0.6) 4.6 (0.7) 4.3 (0.8) 4.6 (0.5)
PCWP, mm Hg 9.0 (1.0) 12.0 (5.0) 10.0 (4.0) 13.0 (8.0)
PVR, Wood units 2.3 (1.4) 2.7 (1.3) 2.7 (2.2) 2.2 (1.1)
PVR index, Wood unitsm2 2.9 (1.8) 3.1 (1.6) 3.4 (0.7) 3.2 (1.5)
Average PA velocity, cm/s 11.0 (2.8) 11.6 (2.5) 11.7 (3.2) 10.9 (1.8)
PA minimal area, cm2 5.4 (2.1) 6.3 (0.7) 7.2 (1.0) 8.0 (1.4)
PA elasticity, % 32.3 (10.7) 36.9 (5.1) 37.7 (6.2) 30.0 (7.1)
Values are median (interquartile range).
PH ¼ pulmonary hypertension; other abbreviations as in Table 1.
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1626velocity and RV ejection fraction) (16) was adequate
(r ¼ 0.83, p < 0.01; mean bias of –1.1 WU and limits of
agreement of –5.9 and 3.7 WU). Serial changes in CMR-
estimated PVR and changes in invasive PVR showed
a good concordance as well (r ¼ 0.86, p < 0.01; mean bias of
–0.14 WU and limits of agreement of –4.7 and 4.4 WU),
although a trend to underestimate large PVR changes was
observed (Fig. 5).
In addition to changes in quantitative parameters, the
appearance of vortices in the ﬂow of the main PA could be
identiﬁed with 3D phase-contrast imaging in all animals
with chronic PH (Fig. 6, Online Videos 1 and 2).
ACUTE VASODILATOR TESTING. Oxygen administration
caused a reduction in PVR (median –2.1 WU, range –3.8 to
0.2 WU) and mean PA pressure (median –7.0 mm Hg,
range –15 to 1 mm Hg), without signiﬁcant changes inTable 3 Baseline and Follow-Up Characteristics of
Baseline 1 Month
Weight, kg 12.5 (2.0) 22.5 (3.0
BSA, m2 0.5 (0.05) 0.7 (0.0
Heart rate, beats/min 120.0 (21.0) 98.0 (18.
Oxygen saturation, % 99.0 (1.0) 90.0 (11.
Mean BP, mm Hg 57.0 (8.0) 77.0 (15.
Mean PA pressure, mm Hg 19.0 (3.0) 30.0 (10.
Cardiac output, l/min 1.9 (0.6) 3.3 (0.8
Cardiac index, l/min/m2 3.6 (0.8) 4.8 (1.1
LVEDP, mm Hg 14.0 (2.0)* 6.0 (3.0
PVR, Wood units 2.5 (1.4) 6.7 (1.5
PVR index, Wood unitsm2 1.0 (0.6) 4.2 (1.1
Average PA velocity, cm/s 14.7 (1.9) 11.0 (3.0
PA minimal area, cm2 1.8 (0.3) 3.7 (1.2
PA elasticity, % 42.9 (12.1) 21.2 (10.
Values are median (interquartile range). *Pulmonary wedge pressure at end-e
BSA ¼ body surface area; LVEDP ¼ left ventricular end-diastolic pressure;cardiac output (median 0.0 l/m, range –0.8 to 0.5 l/min).
These hemodynamic changes were accompanied by a
signiﬁcant increase in PA velocity, an increase in PA elas-
ticity, and a reduction in PA area (Table 4).
The change in PA velocity strongly correlated with the
reduction in PVR (r ¼ –0.89, p ¼ 0.01) (Fig. 3C) and mean
PA pressure (r ¼ –0.86, p ¼ 0.02). Baseline PA elasticity
(before vasodilator testing) signiﬁcantly correlated with the
change in PVR (r ¼ 0.73, p ¼ 0.04) but the acute change in
PVR did not correlate with the acute change in PA area or
elasticity.
Histopathologic examination. Chronic PH generation
was associated in both experimental models with typical
changes of arterial intimal proliferation, hypertrophy of the
media and perivascular ﬁbrosis of vessels inside the lung,
hypertrophy and increased collagen deposition in the mediaChronic Post-Capillary PH Group
2 Months 3 Months 4 Months
) 40.0 (10.5) 57.3 (11.0) 80.5 (5.5)
6) 1.0 (0.2) 1.3 (0.1) 1.6 (0.1)
0) 74.0 (14.0) 68.0 (9.5) 62.0 (11.0)
0) 91.0 (6.0) 93.0 (4.0) 95.0 (3.0)
0) 92.5 (17.5) 93.5 (12.5) 91.0 (7.0)
0) 36.0 (14.0) 34.5 (14.0) 35.0 (8.0)
) 4.4 (1.4) 5.9 (1.0) 6.8 (2.7)
) 4.3 (1.0) 4.3 (0.7) 4.3 (1.1)
) 8.0 (2.0) 9.0 (3.5) 9.0 (4.0)
) 7.1 (4.6) 4.0 (2.1) 3.7 (1.0)
) 6.4 (5.2) 5.8 (3.2) 6.2 (2.2)
) 11.0 (2.9) 11.4 (1.8) 11.5 (2.9)
) 5.4 (2.1) 6.3 (1.9) 7.8 (1.3)
8) 32.5 (8.3) 35.2 (19.0) 31.6 (21.2)
xpiration was used instead of EDLVP at baseline.
other abbreviations as in Tables 1 and 2.
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Figure 4 Example of 8 Cases of Chronic PH
Cases illustrating the concordance between the evolution of pulmonary vascular resistance and average pulmonary artery velocity during the follow-up. PH ¼ pulmonary
hypertension; other abbreviations as in Figure 3.
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1627of the main PA, and RV dilatation, hypertrophy and
myocardial ﬁbrosis and disarray (Fig. 7).
Discussion
The main ﬁndings of this study are the following: 1) CMR
allows noninvasive monitoring of serial changes in PVR in−
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Correlation (A) and Bland-Altman plot (B) showing the association between changes in P
estimated based on cardiac magnetic resonance (CMR) data (CMR-quantiﬁed PVR). Abbrchronic PH; 2) semiquantitative monitoring can be per-
formed by determining simple changes in average PA ﬂow
velocity; and 3) variations in average PA velocity additionally
have the ability to track acute increases or decreases in PVR.
PVRmonitoring by RHC is recommended in patients with
chronic PH and those with heart failure awaiting heart
transplantation (2). It has been recently reported that−
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Figure 6 Three-Dimensional Phase Contrast Imaging of the Main Pulmonary Artery
(A) Control animal without pulmonary hypertension showing laminar ﬂow. (B) Case of post-capillary pulmonary hypertension showing turbulent ﬂow and formation of a ﬂow vortex
in the main pulmonary artery (arrow). Please see Online Videos 1 and 2.
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1628a method combining the average PA velocity and RV ejection
fraction, both measured by CMR, allowed noninvasive esti-
mation of PVR in patients with chronic PH at a single time
point (16). In the present study we further evaluated whether
this approach would be able tomonitor serial changes in PVR,
and therefore its potential for noninvasive follow-up, in
experimental models of chronic PH. The 2 models employed
led to the expected abnormalities not only in hemodynamics
but also in cardiovascular adaptation to chronic pressure
overload, as conﬁrmed by the changes in the heart and
pulmonary artery demonstrated in histopathological analyses
(Fig. 7). Overall, PVR tended to increase initially and stabilize
during follow-up. However, some subjects showed reduction
of PVR between visits due to adaptation mechanisms, which
allowed us to evaluate the accuracy ofCMR to track changes in
PVR on both directions. This mimics clinical PH, with
between-visits PVR increase due to disease progression or
reduction with treatment. We were able to replicate the
accuracy of the previously reported CMRmethod (16) in this
experimental setting again with narrower limits of agreementTable 4 Changes in Hemodynamic and Phase Con
Baseline Post-Vas
Heart rate, beats/min 73.5 (21.0) 74.5
Oxygen saturation, % 89.0 (5.0) 98
Mean BP, mm Hg 85.5 (34.0) 95.0
Mean PA pressure, mm Hg 36.5 (14.0) 27.5
Cardiac output, l/min 4.7 (2.1) 4.5
PCWP, mm Hg 9.0 (5.0) 8.2
PVR, Wood units 4.9 (2.8) 3.4
PA ﬂow velocity, cm/s 9.8 (2.4) 11.9
PA minimal area, cm2 5.8 (3.9) 4.3
PA elasticity, % 28.2 (14.0) 34.2
Values at baseline and post-vasodilator test are median (interquartile range)
Abbreviations as in Table 1.than those reported with echocardiography (10,22,23) and,
most importantly, demonstrate its ability to track variations in
PVR over time.
The combination of RV ejection fraction and average PA
velocity enables absolute quantiﬁcation of PVR; however, it
also adds complexity and scanning time. Based on previous
studies (15,16), we focused on changes in average PA
velocity alone as an alternative method, as this was the
parameter with the strongest correlations with PVR and the
highest weight in the predictive model. In addition, PA
velocity can be easily and rapidly quantiﬁed, and is more
likely to reveal acute changes in hemodynamic conditions
than parameters that reﬂect structural adaptation to chronic
PH such as RV ejection fraction or PA dimensions. The
presence of low PA velocities by CMR in patients with
chronic PH has been long recognized (24,25). There are
several mechanisms that may contribute to the tight relation
between changes in PVR and changes in PA ﬂow velocity.
Increased PVR in chronic PH is associated with vasocon-
striction and remodeling of distal vessels, so blood transittrast Parameters During Vasodilator Testing
odilator Test Change p Value
(23.0) 6.0 (14.0 to 12.0) 0.15
(2.0) 10.0 (6.0 to 18.0) <0.01
(49.7) 0.5 (9 to 22) 0.61
(19.0) 7.0 (–15.0 to –1.0) <0.01
(2.5) 0.0 (–0.8 to 0.5) 0.88
(5.0) 0.2 (–1 to 0) 1.00
(4.1) 2.1 (–3.8 to 0.2) <0.01
(3.1) 1.5 (0.4 to 4.2) <0.01
(3.7) 1.2 (–1.8 to –0.6) 0.01
(24.8) 9.7 (32 to 5) 0.04
and change is expressed as median (minimum to maximum).
Figure 7 Example of Pathology Changes in a Case of Post-Capillary PH and in a Case of Pre-Capillary PH
(A) Masson’s trichrome staining showing increased collagen ﬁbers in the tunica media of the main pulmonary artery (PA). (B) Picrosirius red staining of the right ventricular (RV)
free wall showing myocardial disarray and ﬁbrosis (arrows). (C) Cross section of the heart showing marked RV hypertrophy and dilatation. (D) Masson’s trichrome staining
showing arterial intimal proliferation (arrows) and hypertrophy of the media (arrowheads) in the middle pulmonary lobe. (E) Masson’s trichrome staining showing increased
collagen ﬁbers in the media of the main PA (arrow), disarray of smooth muscle cells (arrowheads), and intimal ﬁbrosis (asterisk). (F) Masson’s trichrome staining showing
arterial medial hypertrophy and crescent-like ﬁbrous intimal cushion (arrowheads) that causes luminal narrowing and adventitial thickening (arrows). (G) Picrosirius red staining
of the RV free wall showing myocardial ﬁbrosis (arrows). (H) Masson’s trichrome staining showing adventitial thickening and vasculitis with transmural inﬁltration of
lymphocytes (arrowheads). Obliteration, ﬁbrosis, and recanalization of a thrombosed pulmonary artery (arrows). LV ¼ left ventricle; PH ¼ pulmonary hypertension.
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1629through the pulmonary tree is hampered. Increased PVR
subsequently causes PA dilatation and associated changes
of ﬂow pattern characterized by the presence of systolicretrograde ﬂow (24) and the formation of ﬂow vortices (21)
(as shown in Fig. 6, Online Videos 1 and 2). Finally, as PH
progresses, the RV fails and cardiac output tends to decrease.
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1630The combination of all these mechanisms causes, for any
given ﬂow and PA pressure, a reduction in average velocity.
In contrast with other techniques such as Doppler echo-
cardiography or catheter-tip velocity transducer, CMR
allows for average ﬂow velocity from the complete PA cross-
sectional area through the entire cardiac cycle avoiding the
wrong assumption of a uniform PA ﬂow proﬁle.
For the objective of monitoring changes in PVR during
follow-up, PA velocity alone performed as well as the more
complex method and is signiﬁcantly simpler. As additional
advantages, 2D ﬂow imaging is easily acquired during free
breathing, does not require contrast agent administration,
and is easily processed with high intraobserver and inter-
observer reproducibility (16). Correlations with PVR varia-
tions were stronger in the post-capillary compared to the
pre-capillary model, probably because the range of PVR
changes was wider. In a prior small study of chronic PH
patients with serial RHC and CMR performed at 2 different
time points, it was observed that changes in PA velocities or
dimensions differed between patients who experienced
hemodynamic improvement during follow-up (26). Our
present study with simultaneous hemodynamic assessment
strengthens this observation without the limitations of per-
forming tests on different days with potential signiﬁcant
variations in PVR. Based on our results, we believe that in
the presence of clinical stability and RV function stability (as
can be accurately assessed by CMR), an increase or main-
tenance of average PA velocity could serve to delay or space
RHC studies. Further studies will help to elucidate the
precise role that CMR may play to monitor patients with
chronic PH.
A previous study (27) showed that PA distensibility, as
assessed by CMR, was signiﬁcantly higher in patients with
a positive response in vasodilator testing performed within
48 h. To our knowledge, ours is the ﬁrst study of simulta-
neous CMR imaging and hemodynamic invasive assessment
during acute vasodilator testing. Beyond the ability to detect
serial PVR changes in chronic PH, we conﬁrmed the
hypothesized dynamic response of PA velocity to hemody-
namic conditions and demonstrated strong correlations
between acute ﬂuctuations in average PA velocity and PVR.
Consequently, another interesting and potential application
of noninvasive PVR monitoring with CMR could be the
evaluation of pulmonary vascular reactivity. Our results
suggest that vasodilator testing could be incorporated into
the comprehensive CMR study of chronic PH patients.
Several medications might be used as vasodilators. We
decided to use high oxygen dose due to its availability, easy
administration, safety, and demonstrated effect in experi-
mental PH models (18). Moreover, oxygen has been tradi-
tionally used for vasodilator testing in pediatric patients (28),
a population especially attractive to conduct noninvasive
evaluation avoiding radiation and instrumentation.
Study limitations. Some limitations of this investigation
should be acknowledged. CMR-compatible Swan-Ganz
catheters do not have thermistor, so the value of cardiacoutput used for the calculation of PVR during CMR in the
acute models was not derived from thermodilution (the gold
standard) but from phase-contrast imaging. However,
phase-contrast is well validated and we could demonstrate an
excellent correlation between both techniques when ther-
modilution was performed immediately before imaging and
all conditions were steady state. We applied the temporal
resolution typically used in clinical evaluations as a compro-
mise between quality and acquisition time. The pre-capillary
PH model generated by repeated pulmonary embolizations
created only mild PH as compared with the post-capillary
model. Although it was helpful to evaluate the behavior of
serial cardiac MR imaging with mild changes or stability of
PVR and to test the CMR method in 2 different models of
chronic PH, it has to be recognized that PH severity was low
in the pre-capillary model. Related with this issue, the range
of PVR changes along the follow-up was narrower, which
may explain the lower correlation between changes in PVR
and PA velocity, as compared with the post-capillary model.
Further studies are needed to evaluate the utility of nonin-
vasive CMR monitoring in patients with severe pre-capillary
PH and to conﬁrm the correlation between acute change in
average PA velocity and acute reduction in PVR using other
vasodilators such as nitric oxide or epoprostenol.
Conclusions
CMR allows noninvasive monitoring of serial changes of
PVR in chronic PH and the acute response of PVR during
vasodilator testing. This may be of great value in the eval-
uation and follow-up of patients with chronic PH.
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APPENDIX
For supplemental videos, please see the online version of this article.
